TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR
The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering a HER2/4-1BB-bispecific agent and a HER2-targeted tyrosine kina...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WALKER, Luke BEL AIBA, Rachida JAQUIN, Thomas OLWILL, Shane HEINIG, Kristina ZETTL, Markus |
| description | The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering a HER2/4-1BB-bispecific agent and a HER2-targeted tyrosine kinase inhibitor (TKI). The disclosure further provides combinations and kits of parts comprising a HER2/4-1 BB-bispecific agent and a HER2-targeted TKI.
L'invention concerne des procédés et des compositions pour traiter des tumeurs, en particulier des tumeurs exprimant HER2, y compris des tumeurs caractérisées par une faible expression de tumeurs HER2 et HER2- positives (HER2+). Le procédé comprend l'administration d'un agent bispécifique anti-HER2/4-1BB et d'un inhibiteur de tyrosine kinase (TKI) ciblant HER2. L'invention concerne en outre des combinaisons et des kits de parties comprenant un agent bispécifique anti-HER2/4-1BB et un TKI ciblant HER2. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022200478A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022200478A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022200478A13</originalsourceid><addsrcrecordid>eNqNys8KgkAQgHEvHaJ6h4HOkm6CXWd1dIdwN9YJ6WQS2ylKsPenP_QAnb7D95tHZzk2zoN4QmnICnQsBhCyONV6Y8irWHN7oIIrLgDrD0FbvsX3CfqahEqQk3ctW4I9W2wJ2BrWLM4vo9l1uE1h9esiWlckhYnD-OjDNA6XcA_PvnMqUUolSZbvMN3-p17gVTOa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR</title><source>esp@cenet</source><creator>WALKER, Luke ; BEL AIBA, Rachida ; JAQUIN, Thomas ; OLWILL, Shane ; HEINIG, Kristina ; ZETTL, Markus</creator><creatorcontrib>WALKER, Luke ; BEL AIBA, Rachida ; JAQUIN, Thomas ; OLWILL, Shane ; HEINIG, Kristina ; ZETTL, Markus</creatorcontrib><description>The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering a HER2/4-1BB-bispecific agent and a HER2-targeted tyrosine kinase inhibitor (TKI). The disclosure further provides combinations and kits of parts comprising a HER2/4-1 BB-bispecific agent and a HER2-targeted TKI.
L'invention concerne des procédés et des compositions pour traiter des tumeurs, en particulier des tumeurs exprimant HER2, y compris des tumeurs caractérisées par une faible expression de tumeurs HER2 et HER2- positives (HER2+). Le procédé comprend l'administration d'un agent bispécifique anti-HER2/4-1BB et d'un inhibiteur de tyrosine kinase (TKI) ciblant HER2. L'invention concerne en outre des combinaisons et des kits de parties comprenant un agent bispécifique anti-HER2/4-1BB et un TKI ciblant HER2.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220929&DB=EPODOC&CC=WO&NR=2022200478A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220929&DB=EPODOC&CC=WO&NR=2022200478A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WALKER, Luke</creatorcontrib><creatorcontrib>BEL AIBA, Rachida</creatorcontrib><creatorcontrib>JAQUIN, Thomas</creatorcontrib><creatorcontrib>OLWILL, Shane</creatorcontrib><creatorcontrib>HEINIG, Kristina</creatorcontrib><creatorcontrib>ZETTL, Markus</creatorcontrib><title>TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR</title><description>The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering a HER2/4-1BB-bispecific agent and a HER2-targeted tyrosine kinase inhibitor (TKI). The disclosure further provides combinations and kits of parts comprising a HER2/4-1 BB-bispecific agent and a HER2-targeted TKI.
L'invention concerne des procédés et des compositions pour traiter des tumeurs, en particulier des tumeurs exprimant HER2, y compris des tumeurs caractérisées par une faible expression de tumeurs HER2 et HER2- positives (HER2+). Le procédé comprend l'administration d'un agent bispécifique anti-HER2/4-1BB et d'un inhibiteur de tyrosine kinase (TKI) ciblant HER2. L'invention concerne en outre des combinaisons et des kits de parties comprenant un agent bispécifique anti-HER2/4-1BB et un TKI ciblant HER2.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNys8KgkAQgHEvHaJ6h4HOkm6CXWd1dIdwN9YJ6WQS2ylKsPenP_QAnb7D95tHZzk2zoN4QmnICnQsBhCyONV6Y8irWHN7oIIrLgDrD0FbvsX3CfqahEqQk3ctW4I9W2wJ2BrWLM4vo9l1uE1h9esiWlckhYnD-OjDNA6XcA_PvnMqUUolSZbvMN3-p17gVTOa</recordid><startdate>20220929</startdate><enddate>20220929</enddate><creator>WALKER, Luke</creator><creator>BEL AIBA, Rachida</creator><creator>JAQUIN, Thomas</creator><creator>OLWILL, Shane</creator><creator>HEINIG, Kristina</creator><creator>ZETTL, Markus</creator><scope>EVB</scope></search><sort><creationdate>20220929</creationdate><title>TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR</title><author>WALKER, Luke ; BEL AIBA, Rachida ; JAQUIN, Thomas ; OLWILL, Shane ; HEINIG, Kristina ; ZETTL, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022200478A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>WALKER, Luke</creatorcontrib><creatorcontrib>BEL AIBA, Rachida</creatorcontrib><creatorcontrib>JAQUIN, Thomas</creatorcontrib><creatorcontrib>OLWILL, Shane</creatorcontrib><creatorcontrib>HEINIG, Kristina</creatorcontrib><creatorcontrib>ZETTL, Markus</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WALKER, Luke</au><au>BEL AIBA, Rachida</au><au>JAQUIN, Thomas</au><au>OLWILL, Shane</au><au>HEINIG, Kristina</au><au>ZETTL, Markus</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR</title><date>2022-09-29</date><risdate>2022</risdate><abstract>The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering a HER2/4-1BB-bispecific agent and a HER2-targeted tyrosine kinase inhibitor (TKI). The disclosure further provides combinations and kits of parts comprising a HER2/4-1 BB-bispecific agent and a HER2-targeted TKI.
L'invention concerne des procédés et des compositions pour traiter des tumeurs, en particulier des tumeurs exprimant HER2, y compris des tumeurs caractérisées par une faible expression de tumeurs HER2 et HER2- positives (HER2+). Le procédé comprend l'administration d'un agent bispécifique anti-HER2/4-1BB et d'un inhibiteur de tyrosine kinase (TKI) ciblant HER2. L'invention concerne en outre des combinaisons et des kits de parties comprenant un agent bispécifique anti-HER2/4-1BB et un TKI ciblant HER2.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2022200478A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T22%3A15%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WALKER,%20Luke&rft.date=2022-09-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022200478A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |